India, Dec. 12 -- Shares of Trevi Therapeutics, Inc. (TRVI) surged over 60% on Thursday morning after the company reported a positive outcome from sample size re-estimation for phase 2b CORAL study. TRVI is currently trading at $4.0000, up $1.5100 or 60.6426%, on the Nasdaq. The stock opened its trading at $3.9050 after closing Wednesday at $2.4900. The stock has traded between $1.2200 and $4.5000 in the past 52-week period.
Trevi Therapeutics reported positive outcomes from sample size re-estimation for the ongoing Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) who have a chronic cough. The clinical-stage biopharmaceutical company's shares were surging more than 80 percent in pre-market.
Based on the Sample siz...